{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:08:43Z","timestamp":1768000123212,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,11,25]],"date-time":"2013-11-25T00:00:00Z","timestamp":1385337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,11,25]],"date-time":"2013-11-25T00:00:00Z","timestamp":1385337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1038\/bmt.2013.187","type":"journal-article","created":{"date-parts":[[2013,11,25]],"date-time":"2013-11-25T11:41:06Z","timestamp":1385379666000},"page":"416-421","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Second transplants for multiple myeloma relapsing after a previous autotransplant\u2014reduced-intensity allogeneic vs autologous transplantation"],"prefix":"10.1038","volume":"49","author":[{"given":"C O","family":"Freytes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D H","family":"Vesole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"LeRademacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R P","family":"Gale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R A","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D E","family":"Reece","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H C","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P L","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A Y","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P N","family":"Hari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,25]]},"reference":[{"key":"BFbmt2013187_CR1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nrclinonc.2011.63","volume":"8","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV . Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8: 479\u2013491.","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 1","key":"BFbmt2013187_CR2","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1053\/j.seminhematol.2012.05.003","volume":"49","author":"J Jacubowiak","year":"2012","unstructured":"Jacubowiak J . Management strategies for relapsed\/refractory multiple myeloma: current clinical perspectives. Semin Hematol 2012; 49 (Suppl 1): S16\u2013S32.","journal-title":"Semin Hematol"},{"key":"BFbmt2013187_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/leu.2011.196","volume":"26","author":"SK Kumar","year":"2012","unstructured":"Kumar SK, Lee JH, LaHuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149\u2013157.","journal-title":"Leukemia"},{"key":"BFbmt2013187_CR4","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1038\/bmt.2012.1","volume":"47","author":"W Bensinger","year":"2012","unstructured":"Bensinger W, Rotta M, Storer B, Chauncey T, Holmberg L, Becker P et al. Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center. Bone Marrow Transplant 2012; 47: 1312\u20131317.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2013187_CR5","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628\u20131633.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2013187_CR6","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.bbmt.2008.04.003","volume":"14","author":"D Weisdorf","year":"2008","unstructured":"Weisdorf D, Spellman S, Haagenson M, Horowitz M, Lee S, Anasetti C et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008; 14: 748\u2013758.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2013187_CR7","doi-asserted-by":"crossref","DOI":"10.1007\/b97377","volume-title":"Survival Analysis: Techniques of Censored and Truncated Data","author":"J Klein","year":"2003","unstructured":"Klein J, Moeschberger M . Survival Analysis: Techniques of Censored and Truncated Data 2nd edn. Springer-Verlag: New York, NY, USA, 2003)."},{"key":"BFbmt2013187_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457\u2013481.","journal-title":"J Am Stat Assoc"},{"key":"BFbmt2013187_CR9","first-page":"825","volume":"15","author":"D Przepiorka","year":"1994","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825\u2013828.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2013187_CR10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR . Regression models and life tables. J R Stat Soc 1972; 34: 187\u2013220.","journal-title":"J R Stat Soc"},{"key":"BFbmt2013187_CR11","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1080\/10428190903085936","volume":"50","author":"JA Burzynski","year":"2009","unstructured":"Burzynski JA, Toro JJ, Patel RC, Lee S, Greene RE, Ochoa-Bayona JL et al. Toxicity of a second autologous peripheral blood transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymphoma 2009; 50: 1442\u20131447.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2013187_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/bmt.2008.334","volume":"43","author":"RL Olin","year":"2009","unstructured":"Olin RL, Vogl DT, Porter DL, Luger SM, Schuster SJ, Tsai DE et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant 2009; 43: 417\u2013422.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2013187_CR13","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.3109\/10428194.2011.575967","volume":"52","author":"R Fenk","year":"2011","unstructured":"Fenk R, Liese V, Neubauer F, Bruns I, Kondakci M, Balleisen S et al. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leuk Lymphoma 2011; 52: 1455\u20131462.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2013187_CR14","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.bbmt.2011.10.044","volume":"18","author":"VH Jimenez-Zepeda","year":"2012","unstructured":"Jimenez-Zepeda VH, Mikhael J, Winter A, Franke N, Masih-Khan E, Trudel S et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant 2012; 18: 773\u2013779.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2013187_CR15","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1002\/cncr.26662","volume":"118","author":"N Shah","year":"2012","unstructured":"Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G et al. Durable remissions with salvage second autotransplants in patients with multiple myeloma. Cancer 2012; 118: 3549\u20133555.","journal-title":"Cancer"},{"key":"BFbmt2013187_CR16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1445-5994.2012.02867.x","volume":"43","author":"AW Chow","year":"2013","unstructured":"Chow AW, Lee CH, Hiwase DK, To LB, Horvath N . Relapsed multiple myeloma: who benefits from salvage autografts? Intern Med J 2013; 43: 156\u2013161.","journal-title":"Intern Med J"},{"key":"BFbmt2013187_CR17","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.bbmt.2013.01.004","volume":"19","author":"LC Michaelis","year":"2013","unstructured":"Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI et al. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant. 2013; 19: 760\u2013766.","journal-title":"Biol Blood Marrow Transplant."},{"key":"BFbmt2013187_CR18","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1182\/blood.V97.9.2574","volume":"97","author":"A Badros","year":"2001","unstructured":"Badros A, Barlogie B, Morris C, Desikan R, Martin SR, Munshi N et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001; 97: 2574\u20132579.","journal-title":"Blood"},{"key":"BFbmt2013187_CR19","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1182\/blood-2002-04-1150","volume":"100","author":"N Kroger","year":"2002","unstructured":"Kroger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919\u20133924.","journal-title":"Blood"},{"key":"BFbmt2013187_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1046\/j.1365-2141.2003.04299.x","volume":"121","author":"H Einsele","year":"2003","unstructured":"Einsele H, Schafer HJ, Hebart H, Bader P, Meisner C, Plasswilm L et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 2003; 121: 411\u2013418.","journal-title":"Br J Haematol"},{"key":"BFbmt2013187_CR21","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/sj.bmt.1705161","volume":"36","author":"S Gerull","year":"2005","unstructured":"Gerull S, Goerner M, Benner A, Hegenbart U, Klein U, Schaefer H et al. Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant 2005; 36: 963\u2013969.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2013187_CR22","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/sj.leu.2404085","volume":"20","author":"JA P\u00e9rez-Sim\u00f3n","year":"2006","unstructured":"P\u00e9rez-Sim\u00f3n JA, Sureda A, Fern\u00e1ndez-Aviles F, Sampol A, Cabrera JR, Caballero D et al. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia 2006; 20: 542\u2013545.","journal-title":"Leukemia"},{"key":"BFbmt2013187_CR23","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/cncr.21700","volume":"106","author":"MH Qazilbach","year":"2006","unstructured":"Qazilbach MH, Saliba R, De Lima M, Hosing C, Couriel D, Aleman A et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 2006; 106: 1084\u20131089.","journal-title":"Cancer"},{"key":"BFbmt2013187_CR24","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.bbmt.2006.11.011","volume":"13","author":"GE Georges","year":"2007","unstructured":"Georges GE, Maris MB, Maloney DG, Sandmaier BM, Sorror ML, Shizuru JA et al. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Biol Blood Marrow Transplant 2007; 13: 423\u2013432.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2013187_CR25","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/10428190601186150","volume":"48","author":"I Majolino","year":"2007","unstructured":"Majolino I, Davoli M, Carnevalli E, Locasciulli A, Di Bartolomeo P, Scime R et al. Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma. Leuk Lymphoma 2007; 48: 759\u2013766.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2013187_CR26","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/bmt.2008.22","volume":"41","author":"H De Lavallade","year":"2008","unstructured":"De Lavallade H, El-Cheikh J, Faucher C, Furst S, Stoppa AM, Coso D et al. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant 2008; 41: 953\u2013960.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2013187_CR27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/ajh.21633","volume":"85","author":"K Osman","year":"2010","unstructured":"Osman K, Elliot B, Mandeli J, Scigliano E, Malone A, Isola L et al. Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma. Am J Hematol 2010; 85: 249\u2013254.","journal-title":"Am J Hematol"},{"key":"BFbmt2013187_CR28","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1002\/cncr.25228","volume":"116","author":"A Shimoni","year":"2010","unstructured":"Shimoni A, Hardan I, Ayuk F, Schilling G, Atanackovic D, Zeller W et al. Allogenic hematopoietic stem cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma. Cancer 2010; 116: 3621\u20133630.","journal-title":"Cancer"},{"key":"BFbmt2013187_CR29","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2004-06-2387","volume":"105","author":"C Crawley","year":"2005","unstructured":"Crawley C, Lallancete M, Szydlo R, Gilleece M, Peggs K, Mackinnon S et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors of the Leukemia Working Party of the EBMT. Blood 2005; 105: 4532\u20134539.","journal-title":"Blood"},{"key":"BFbmt2013187_CR30","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","volume":"12","author":"A Krishnan","year":"2011","unstructured":"Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea III E et al. Tandem autologous versus single autologous transplantation followed by allogeneic hematopoietic cell transplantation for patients with multiple myeloma: results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 trial. Lancet Oncol 2011; 12: 1195\u20131203.","journal-title":"Lancet Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2013187.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2013187","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2013187.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T09:46:29Z","timestamp":1716198389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2013187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,25]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["BFbmt2013187"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2013.187","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,25]]},"assertion":[{"value":"8 July 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}